Safety and Efficacy Study of TVGV-1 Vaccine to Treat HPV Induced Cervical HSIL

NCT02576561 | Unknown Phase 2 DMC

• 1 other identifier: VAX 02-01
• Study Type: interventional
• Target: 10
• Locations: 1 country
• Sites: 11

Brief Summary

The purpose of this research study is to test the safety and effectiveness of the investigational study vaccine, called TVGV-1. The study will test the vaccine in women with high grade HPV cervical infection.

Conditions

Human Papillomavirus; High-Grade Squamous Intraepithelial Lesions

Keywords

human papillomavirus; Cervical Intraepithelial Neoplasia; Cold Knife Conization; hysterectomy; Loop Electrosurgical Excision Procedure; LEEP; HSIL; High-Grade Squamous Intraepithelial Lesion

Outcome Measures

Primary Outcomes (2)

• Absence of histologic HSIL (CIN2/3) as assessed by biopsy at last study Visit 11, Day 270.

  The primary analysis for efficacy will be a comparison between subjects treated with and without the PEK fusion protein with respect to the percentage who present regression of HSIL at Day 270. Separate comparisons within each cohort will be performed using Fisher's exact test (or an appropriate analogue). No adjustment for multiple comparisons will be employed in these analyses. Additionally, a corresponding comparison across all study subjects combined will be performed, based on Cochran-Matel-Haenszel test stratified for cohort.

  DAY 270

• Assessment of cutaneous toxicities (i.e., size, induration and time to resolution of skin reactions to vaccine).

  Summaries of the data pertaining to the primary safety outcome of skin toxicity will be provided. Summaries will be provided for the within-cohort subsets of subjects treated with the active, and with the adjuvant alone; and the combined subsets across all three cohorts of subject treated with the active, with the adjuvant alone, and with the placebo. Serious adverse events will be described in narrative with the participant's demographics, treatment date, event, onset date, relationship to the study treatment and the descriptions of the actions and outcomes during this event. Any deaths occurring in the study will be summarized in narrative with the demographics, treatment duration, cause of death, date of death and additional information surrounding that serious adverse event.

  DAY 270

Secondary Outcomes (2)

• Absence of HPV16 in cervical cytological specimen. Absence of cervical dysplasia 6 months and 8 months after last dose of TVGV-1.

  DAY 270

• Assessment of clinical or laboratory findings and other safety variables.

  DAy 270

Study Arms (9)

TVGV-1 (cohort 1)

EXPERIMENTAL

Antigen + Adjuvant - 0.6 mg lyophilized PEK fusion protein + 0.6 ml\* GPI- 0100 (1:1 ratio)

Biological: TVGV-1

GPI-0100 (cohort 1)

ACTIVE COMPARATOR

Adjuvant Alone - 0 mg lyophilized PEK fusion protein. 0.6 mg lyophilized placebo cake + 0.6 ml\* GPI- 0100 (1:1 ratio)

Biological: GPI-0100

Placebo (cohort 1)

PLACEBO COMPARATOR

Placebo- 0 mg lyophilized PEK fusion protein. 0.6 mg lyophilized placebo cake + 0.6 ml placebo-diluent (1:1 ratio)

Biological: Placebo

TVGV-1 (cohort 2)

EXPERIMENTAL

Antigen + Adjuvant - 0.9 mg lyophilized PEK fusion protein + 0.9 ml\* GPI- 0100 (1:1 ratio)

Biological: TVGV-1

GPI-0100 (cohort 2)

ACTIVE COMPARATOR

Adjuvant Alone - 0 mg lyophilized PEK fusion protein. 0.9 mg lyophilized placebo cake + 0.9 ml\* GPI- 0100 (1:1 ratio)

Biological: GPI-0100

Placebo (cohort 2)

PLACEBO COMPARATOR

Placebo - 0 mg lyophilized PEK fusion protein. 0.9 mg lyophilized placebo cake + 0.9 ml placebo diluent (1:1 ratio)

Biological: Placebo

TVGV-1 (cohort 3)

EXPERIMENTAL

Antigen + Adjuvant - 1.2 mg lyophilized PEK fusion protein + 1.2 ml\* GPI- 0100 (1:1 ratio)

Biological: TVGV-1

GPI-0100 (cohort 3)

ACTIVE COMPARATOR

Adjuvant Alone - 0 mg lyophilized PEK fusion protein + 1.2 mg lyophilized placebo cake 1.2 ml\* GPI- 0100 (1:1 ratio)

Biological: GPI-0100

Placebo (cohort 3)

PLACEBO COMPARATOR

Placebo - 0 mg lyophilized PEK fusion protein. 1.2 mg lyophilized placebo cake + 1.2 ml placebo-diluent (1:1 ratio)

Biological: Placebo

Interventions

TVGV-1 BIOLOGICAL

Antigen + Adjuvant

Also known as: lyophilized PEK fusion protein, GPI-0100, Antigen, Adjuvant

TVGV-1 (cohort 1); TVGV-1 (cohort 2); TVGV-1 (cohort 3)

GPI-0100 BIOLOGICAL

Adjuvant Alone

Also known as: Adjuvant

GPI-0100 (cohort 1); GPI-0100 (cohort 2); GPI-0100 (cohort 3)

Placebo BIOLOGICAL

Placebo

Also known as: lyophilized placebo cak, placebo diluent, sterile water

Placebo (cohort 1); Placebo (cohort 2); Placebo (cohort 3)

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Female age 18 to 55 years
• Written informed consent in accordance with institutional guidelines
• Negative pregnancy test (urine and blood tests)
• Women of child bearing potential must agree to use contraception through one menstrual cycle post end of study or if early withdrawal, through what would have been visit 11. Methods include intrauterine device or double barrier method, hormonal contraceptive in combination with a double barrier method.
• Patients who have ONLY HPV 16 OR HPV 16 AND 18 and no other High-Risk HPV by Cobas test will be included.
• Histologically confirmed, positive HSIL of CIN2+ or higher (only CIN2+/3 subjects will be selected) cervical biopsy, confirmed by external (independent) pathologist panel within the 12 weeks prior to enrollment. If the standard care biopsy is not available for evaluation by the independent pathologist, a fresh biopsy and endocervical curettage will be required. The extent of colposcopic HSIL disease should not involve more than two quadrants of the cervix. Biopsies should be taken from each affected quadrant
• Adequate visualization of entire cervix, cervical lesion(s) and squamous-columnar junction
• Normal electrocardiogram (ECG), laboratory values (chemistry, complete blood count) and urinalysis, as judged Grade 0-1 by per National Cancer Institute Common Toxicity Criteria (NCI-CTC)
• Agrees to Loop Electrosurgical Excision Procedure (LEEP), Cold Knife Conization (CKC) or Hysterectomy being performed at the end of study according to the standard-of-care

You may not qualify if:

• History of cancer (excluding basal cell carcinoma of the skin) including cervical cancer
• Eastern Cooperative Oncology Group (ECOG) performance status \>2 (See Appendix G)
• Administration of any blood product within 3 months of enrollment
• Active infection requiring antimicrobial treatment that would interfere with interpretation of adverse events, cutaneous reactions or efficacy. Treatment of minor concurrent infections should be limited to less than 10 days.
• Administration of any vaccine within 8 weeks of enrollment and within 4 weeks for flu vaccine.
• Participation in any study with an investigational compound or device within 30 days prior to signing informed consent
• Any hematologic disorder involving platelets or clotting abnormalities or any condition requiring treatment with transfusions, anticoagulants except platelet inhibitors (NSAIDs as needed for pain are permitted)
• Active drug or alcohol use or dependence that, in the opinion of the Site Investigator, would interfere with adherence to study protocol
• Skin conditions that require consistent use of topical corticosteroids or other local or systemic therapy that may interfere with interpretation or description of skin-related adverse events linked to vaccination
• The standard criteria for prospective clinical trials of medications developed by Drug-Induced Liver Injury Network (established by The National Institute of Diabetes and Digestive and Kidney Diseases) will be used to assess the laboratory test abnormalities. Normal range for these labs will typically be 5 - 40 IU/L for AST; 7 - 56 IU/L for ALT; 0.2 - 1.2 mg/dL for bilirubin. Subjects will be excluded if values are x 2-x 2.5 the upper limit
• Evidence of hematopoietic, cardiovascular, hepatic, renal, neurologic, psychiatric, dermatologic, immune disorder, or other disease that may interfere with assessment of safety or efficacy of vaccine activity as indicated in study objectives
• Any known allergic reaction to vaccine components
• Any other medical condition(s) that, in the judgment of the Site Investigator, might interfere with the study or require treatment that might interfere with the study
• Family member of the investigation study staff
• Pregnant or breast-feeding

Sponsors & Collaborators

• THEVAX Genetics Vaccine: lead
• Clinical Research Management, Inc.: collaborator

Study Sites (11)

Visions Clinical Research - Tucson

Tucson, Arizona, 85712, United States

Location

Red Rocks OBGYN

Lakewood, Colorado, 80228, United States

Location

Progressive Medical Research

Port Orange, Florida, 32127, United States

Location

Comprehensive Clinical Trials, LLC

West Palm Beach, Florida, 33409, United States

Location

Grady Memorial Hospital

Atlanta, Georgia, 30303, United States

Location

ProHEALTH Care Associates LLP

Port Jefferson, New York, 11777, United States

Location

Unified Women's Clinical Research

Raleigh, North Carolina, 27607, United States

Location

Unified Women's Clinical Research

Winston-Salem, North Carolina, 27103, United States

Location

Complete Healthcare for Women

Columbus, Ohio, 43231, United States

Location

Penn Fertility Care/Reproductive Research Unit Univ of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

Location

Insearch-Tidewater Clinical Research

Norfolk, Virginia, 23502, United States

Location

MeSH Terms

Conditions

Squamous Intraepithelial Lesions; Uterine Cervical Dysplasia

Interventions

GPI0100; Antigens; Adjuvants, Pharmaceutic

Condition Hierarchy (Ancestors)

Morphological and Microscopic Findings; Pathological Conditions, Signs and Symptoms; Precancerous Conditions; Neoplasms; Uterine Cervical Diseases; Uterine Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases

Intervention Hierarchy (Ancestors)

Biological Factors; Pharmaceutic Aids; Pharmaceutical Preparations; Specialty Uses of Chemicals; Chemical Actions and Uses

Study Officials

• Frank L Douglas, PhD, MD

  THEVAX Genetics Vaccine

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 9, 2015
• First Posted: October 15, 2015
• Study Start: November 1, 2015
• Primary Completion: May 1, 2018
• Study Completion: September 1, 2018
• Last Updated: October 25, 2017

Record last verified: 2017-10

Locations

US (11)